Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
P30613

UPID:
KPYR_HUMAN

ALTERNATIVE NAMES:
Pyruvate kinase 1; Pyruvate kinase isozymes L/R; R-type/L-type pyruvate kinase; Red cell/liver pyruvate kinase

ALTERNATIVE UPACC:
P30613; O75758; P11973

BACKGROUND:
The enzyme Pyruvate kinase PKLR, also known as Red cell/liver pyruvate kinase, is integral to the metabolic pathway of glycolysis, facilitating the final step of converting phosphoenolpyruvate to pyruvate and generating ATP. This process is vital for maintaining cellular energy balance.

THERAPEUTIC SIGNIFICANCE:
Involvement of Pyruvate kinase PKLR in diseases such as Pyruvate kinase hyperactivity and Pyruvate kinase deficiency of red cells highlights its clinical significance. These conditions, resulting from gene variants, range from mild to severe hemolytic anemia. Targeting Pyruvate kinase PKLR's function offers a promising avenue for developing treatments for these metabolic disorders.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.